The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
Open accessAbstract
The role of p53, as a prognostic factor for survival in lung cancer, is controversial and the purpose of the present systematic review of the literature is to determine this effect. Published studies were identified with the objective to aggregate the available survival results after a methodological assessment using a scale specifically designed by the European Lung Cancer Working Party (ELCWP). To be eligible, a study had to deal with p53 assessment in lung cancer (primary site) only, and to provide a survival comparison according to the p53 status. Among the 74 eligible papers, 30 identified p53 abnormalities as a univariate statistically significant poor prognostic factor and 56 provided sufficient data to allow survival results aggregation. There was no significant difference between the trials that either showed or did not show a prognostic effect of p53 according to the methodological score or to the laboratory technique used. The studies were categorized by histology, disease stage, treatment and laboratory technique. Combined hazard ratios suggested that an abnormal p53 status had an unfavourable impact on survival: in any stage nonsmall cell lung cancer (NSCLC) the mean (95% confidence interval) was 1.44 (1.20–1.72) (number of studies included in the subgroup was 11), 1.50 (1.32–1.70) in stages I–II NSCLC (n=19), 1.68 (1.23–2.29) in stages I–IIIB NSCLC (n=5), 1.68 (1.30–2.18) in stages III–IV NSCLC (n=9), 1.48 (1.29–1.70) in surgically resected NSCLC (n=20), 1.37 (1.02–1.85) in squamous cell carcinoma (n=9), 2.24 (1.70–2.95) in adenocarcinoma (n=9), 1.57 (1.28–1.91) for a positive immunohistochemistry with antibody 1801 (n=8), 1.25 (1.09–1.43) for a positive immunohistochemistry with antibody DO-;7 (n=16), and 1.65 (1.35–2.00) for an abnormal molecular biology test (n=13). Data were insufficient to determine the prognostic value of p53 in small cell lung cancer. In each subgroup of nonsmall cell lung cancer, p53 abnormal status was shown to be associated with a poorer survival prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 1×
“However, not all mutated proteins lose their physiological function and in the case of p53, the disturbance of the regulation of the cell cycle depends on the site of the mutation [101, 102 ].”
BackgroundLarge Trials vs Meta-analysis of Smaller Trials: How Do Their Results Compare?
Cappelleri, J. C. (1996) · JAMA · doi:10.1001/jama.1996.03540160054033 · Cited by 336
Mascaux, C., Paesmans, M., Berghmans, T., Branle, F., Lafitte, J. J., Lemaı̂tre, F., Meert, A. P., Vermylen, P., & Sculier, J. P. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)00127-6 · Cited by 270
Self-citationMaintenance chemotherapy for small cell lung cancer: a critical review of the literature
Sculier, J. P., Berghmans, T., Castaigne, C., Luce, S., Sotiriou, C., Vermylen, P., & Paesmans, M. (1998) · Lung Cancer · doi:10.1016/s0169-5002(97)00084-6 · Cited by 92
Self-citation
Cited by
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Self-citationEvaluation of the Quality of Prognosis Studies in Systematic Reviews
Hayden, J. A., Côté, P., & Bombardier, C. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-6-200603210-00010 · Cited by 1,452
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446
Meert, A.-P., Martin, B., Delmotte, P., Berghmans, T., Lafitte, J.-J., Mascaux, C., Paesmans, M., Steels, E., Verdebout, J.-M., & Sculier, J.-P. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00296502 · Cited by 264
Self-citationBiomarkers in Lung Cancer: From Early Detection to Novel Therapeutics and Decision Making
Scott, A., & Salgia, R. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.6.577 · Cited by 59
Metadata
- Authors
- Steels, E., Paesmans, M., Berghmans, T., Branle, F., Lemaitre, F., Mascaux, C., Meert, A. P., Vallot, F., Lafitte, J. J., & Sculier, J. P.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2001-10
- Volume
- 18
- Issue
- 4
- Pages
- 705-719
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2030196526
- Cited by
- 418
- References
- 6
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. https://app.cochat.ai/papers/10.1183/09031936.01.00062201
- The paper
- Steels, E., Paesmans, M., Berghmans, T., Branle, F., Lemaitre, F., Mascaux, C., Meert, A. P., Vallot, F., Lafitte, J. J., & Sculier, J. P. (2001). Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. European Respiratory Journal. https://doi.org/10.1183/09031936.01.00062201
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
